Physician profile
Stephanie G Schuckalo
NPI 1548234131
$10,740.30
in general payments reported to CMS, 2019-2025
14 companies · $7,558 in 2025
The $7,558 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $320 · 2023: $325 · 2024: $2,278 · 2025: $7,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,750 · Food and Beverage: $1,636 · Travel and Lodging: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,750.00 |
| Food and Beverage | $1,635.68 |
| Travel and Lodging | $774.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $9,081.95 | 2023-2025 | Livmarli, Chenodal, Cholbam |
| Qol Medical, LLC | $425.86 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $409.30 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $272.13 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $251.44 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $54.69 | 2024-2025 | Gattex, Eohilia |
| Genzyme Corporation | $52.41 | 2023-2024 | |
| Travere Therapeutics, INC. | $43.46 | 2022-2023 | Cholbam |
| Alcresta Therapeutics, INC. | $35.82 | 2023-2024 | Relizorb |
| Biocon Biologics INC | $35.57 | 2024-2025 | Yesintek, Hulio |
| Cumberland Pharmaceuticals, INC. | $24.94 | 2022 | |
| Sandoz INC. | $21.09 | 2024 | Hyrimoz |
| Celltrion USA INC. | $17.00 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $14.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Schuckalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.